EKSO - Ekso Bionics Holdings, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.1800
-0.0100 (-0.46%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.1900
Open2.1800
Bid2.15 x 800
Ask2.23 x 1300
Day's Range2.1800 - 2.2400
52 Week Range1.2300 - 3.3000
Volume202,257
Avg. Volume398,796
Market Cap136.56M
Beta (3Y Monthly)1.94
PE Ratio (TTM)N/A
EPS (TTM)-0.53
Earnings DateMay 7, 2018 - May 11, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • Do Institutions Own Shares In Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)?
    Simply Wall St.17 days ago

    Do Institutions Own Shares In Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)?

    If you want to know who really controls Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), then you'll have to look at the makeup of its share registry. Insiders often own a large Read More...

  • ACCESSWIRE17 days ago

    4 Healthcare Stocks Looking To Finish Strong On Wednesday (1/30/19)

    Premier Health Group (PHGRF) (PHGI), China SXT Pharmaceuticals Inc (SXTC), eHealth Inc (EHTH), and Ekso Bionics Holdings Inc (EKSO) represent four healthcare companies determined to provide the best quality of care for consumers in need. The Company has seen impressive gains over the last few months as a result of momentum gained from several key strategic investments meant to demonstrate to both investors and consumers that the Company is determined to invest in the future of its customers. Premier Health Group (PHGRF) (PHGI) announced earlier this week that, further to its new release dated January 10, 2019, the Company has acquired all outstanding securities of Cloud Practice Inc. As a result of the acquisition, Cloud Practice's Founders, including CEO Jordan Visco, and entire support team, consisting of several software developers and sales staff, will join and work alongside the Premier Health team to offer tools and resources providing for better efficiency on a day-to-day basis for both physicians and customers.

  • GlobeNewswire18 days ago

    Ekso Bionics Announces $100 Million Joint Venture to Develop the Exoskeleton Market in Asia

    Ekso Bionics Holdings, Inc. (EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that its wholly-owned subsidiary, Ekso Bionics, Inc., has entered into an agreement with Zhejiang Youchuang Venture Capital Investment Co., Ltd (ZYVC) and another partner to establish a joint venture designed to develop and serve the exoskeleton market in China and other Asian markets and to create a global exoskeleton manufacturing center. Stroke is the leading cause of death in China, and about 2 million Chinese die of stroke-related illnesses every year.  There are currently 12 million stroke patients in the country and the number is expected to more than double to 30 million by 2030.

  • GlobeNewswirelast month

    Ekso Bionics Reports Preliminary Fourth Quarter and Full Year 2018 Financial Results

    Ekso Bionics Holdings, Inc. (EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced preliminary top line financial results for the fourth quarter and fiscal year ended December 31, 2018. Total revenue for the fourth quarter of 2018 is an estimated $3.3 million reflecting year-over-year growth of 32% compared to total revenue of $2.5 million in the fourth quarter of 2017. Total revenue for the fourth quarter of 2018 includes approximately $2.4 million in medical revenue.

  • Simply Wall St.2 months ago

    How Financially Strong Is Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)?

    While small-cap stocks, such as Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) with its market cap of US$103m, are popular for their explosive growth, investors should also be aware of their balance Read More...

  • GlobeNewswire2 months ago

    Worldwide Adoption of Ekso Bionics® EksoGT™ Exoskeleton Allows Stroke and Spinal Cord Injury Patients to Take 100 Million Steps to Date

    Ekso Bionics Holdings, Inc. (EKSO), an industry leader in exoskeleton technology for medical and industry use, today announced that the worldwide adoption of the EksoGT™ exoskeleton has allowed stroke and spinal cord injury patients to take 100 million steps to date (click to tweet). More than 240 leading rehabilitation centers in over 30 countries helped their patients walk 50,000 miles in the EksoGT exoskeleton— the distance of walking around the world twice. Centers utilizing the EksoGT are advancing both in-patient and outpatient rehabilitation, and collectively changing the standard of care to promote better patient outcomes.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of EKSO earnings conference call or presentation 7-Nov-18 9:30pm GMT

    Q3 2018 Ekso Bionics Holdings Inc Earnings Call

  • Ekso Bionics (EKSO) Reports Q3 Loss, Lags Revenue Estimates
    Zacks3 months ago

    Ekso Bionics (EKSO) Reports Q3 Loss, Lags Revenue Estimates

    Ekso Bionics (EKSO) delivered earnings and revenue surprises of -22.22% and -10.87%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 months ago

    Ekso Bionics: 3Q Earnings Snapshot

    The Richmond, California-based company said it had a loss of 11 cents per share. The robotic exoskeleton company posted revenue of $2.6 million in the period. In the final minutes of trading on Wednesday, ...

  • How Ekso Bionics Holdings Inc (NASDAQ:EKSO) Can Impact Your Portfolio Volatility
    Simply Wall St.5 months ago

    How Ekso Bionics Holdings Inc (NASDAQ:EKSO) Can Impact Your Portfolio Volatility

    If you own shares in Ekso Bionics Holdings Inc (NASDAQ:EKSO) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a Read More...

  • Reuters5 months ago

    Ottobock reaches for growth with industrial exoskeletons

    German artificial limb manufacturer Ottobock (IPO-OBH.F) plans to start selling a mechanical exoskeleton that makes manual labor for factory workers easier this week, joining a field already crowded with major industrial players and start-ups. The family-owned company has tested the 'Paexo', a wearable upper-body exoskeleton designed to ease the physical strain of repetitive overhead assembly work, on 30 workers at a Volkswagen (VOWG_p.DE) plant in Bratislava. After 80 percent of workers said they would recommend it to colleagues, Ottobock is talking to Volkswagen about using the Paexo in series production, said Soenke Roessing, head of Ottobock's Industrials unit.

  • Investopedia6 months ago

    Penny Stocks to Watch for September 2018

    Junior miners turned lower in sympathy with declining gold and silver contracts, while small biotech and medical diagnostic stocks picked up the slack, underpinned by sector funds probing new highs. September has a mixed reputation when it comes to small speculative plays, suggesting that traders focus their attention on penny stocks exhibiting the highest relative strength while avoiding falling knives that may face tax selling pressure in the fourth quarter. Low-priced energy stocks look like wild cards in this equation, with crude oil coming off lows while rising Middle East tensions add to sector buying power.

  • Thomson Reuters StreetEvents6 months ago

    Edited Transcript of EKSO earnings conference call or presentation 7-Aug-18 8:30pm GMT

    Q2 2018 Ekso Bionics Holdings Inc Earnings Call

  • ACCESSWIRE6 months ago

    With Overhang Gone, BTCY Could Generate Triple Digit Returns for Shareholders

    Investors recently long EKSO have made 65% with more potential upside to come. Tandem Diabetes Care, Inc. (TNDM) has traded from $2 to $34/share this year, a gain of over 1700%. This is based on improving commercial success with their diabetes business and another FDA approval in the summer.

  • ACCESSWIRE6 months ago

    Today’s Research Reports on Stocks to Watch: Spark Therapeutics and Ekso Bionics

    Shares of Ekso Bionics saw big gains during the trading day but lost almost 11% in after-hours trading. The company reported second quarter results that didn’t hit estimates. Spark Therapeutics, Inc. shares closed down 27.83% on Tuesday, on significant trading volume compared to usual.

  • Ekso Bionics (EKSO) Reports Q2 Loss, Misses Revenue Estimates
    Zacks6 months ago

    Ekso Bionics (EKSO) Reports Q2 Loss, Misses Revenue Estimates

    Ekso Bionics (EKSO) delivered earnings and revenue surprises of -18.18% and -2.08%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press6 months ago

    Ekso Bionics: 2Q Earnings Snapshot

    On a per-share basis, the Richmond, California-based company said it had a loss of 13 cents. The robotic exoskeleton company posted revenue of $3 million in the period. In the final minutes of trading ...